Wegovy and Mounjaro treatments are recommended for adults with an initial BMI of 30 kg/m² or higher (classed as obese). They are also appropriate for people with a BMI between 27 kg/m² and 30 kg/m² (classed as overweight) if you also have weight-related health issues such as prediabetes, high blood pressure, sleep apnea, high cholesterol, or heart problems.

For individuals from Asian, Black African, African-Caribbean, or Middle Eastern backgrounds, the thresholds for overweight and obese categories are reduced by 2.5 kg/m² to reflect their higher risk at lower BMIs.

Additionally, if an individual is transferring their treatment from another provider and has documented evidence of successful previous use of these medications, a lower BMI threshold may be accepted. This consideration is determined on a case-by-case basis.

Injectable weight loss treatment can be continued until you are in a healthy weight range (BMI equivalent of 25 or 23.5 if minority ethnic groups)